Eliano P Navarese1,2,3, Safi U Khan4, Michalina Kołodziejczak5,3, Jacek Kubica1,3, Sergio Buccheri6, Christopher P Cannon7, Paul A Gurbel8, Stefano De Servi9, Andrzej Budaj10, Antonio Bartorelli11, Daniela Trabattoni11, E Magnus Ohman12, Lars Wallentin6, Matthew T Roe12, Stefan James6. 1. Departments of Cardiology and Internal Medicine (E.P.N., J.K.), Nicolaus Copernicus University, Antoni Jurasz University Hospital No. 1, Bydgoszcz, Poland. 2. Faculty of Medicine, University of Alberta, Edmonton, Canada (E.P.N.,). 3. Systematic Investigation and Research on Interventions and Outcomes (SIRIO) MEDICINE Research Network, Bydgoszcz, Poland (E.P.N., M.K., J.K.). 4. Department of Internal Medicine, West Virginia University, Morgantown (S.U.K.). 5. Anaesthesiology and Intensive Care (M.K.), Nicolaus Copernicus University, Antoni Jurasz University Hospital No. 1, Bydgoszcz, Poland. 6. Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University Hospital, Sweden (S.B., L.W., S.J.). 7. Harvard Clinical Research Institute, Boston, MA (C.P.C.). 8. Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, LifeBridgehealth, MD (P.A.G.). 9. IRCCS Multimedica, Sesto San Giovanni, Milan, Italy (S.D.S.). 10. Centre of Postgraduate Medical Education, Grochowski Hospital, Warsaw, Poland (A. Budaj). 11. Centro Cardiologico Monzino, University of Milan, Italy (A. Bartorelli, D.T.). 12. Division of Cardiology, Duke University Medical Center, Durham, NC (E.M.O., M.T.R.).
Abstract
BACKGROUND: New randomized, controlled trials have become available on oral P2Y12 inhibitors in acute coronary syndrome. We aimed to evaluate current evidence comparing the efficacy and safety profile of prasugrel, ticagrelor, and clopidogrel in acute coronary syndrome by a meta-analysis of randomized controlled trials. METHODS: We performed a network meta-analysis and direct pairwise comparison analysis of efficacy and safety outcomes from 12 randomized controlled trials including a total of 52 816 patients with acute coronary syndrome. RESULTS: In comparison with clopidogrel, ticagrelor significantly reduced cardiovascular mortality (hazard ratio [HR], 0.82 [95% CI, 0.72-0.92]) and all-cause mortality (HR, 0.83 [95% CI, 0.75-0.92]), whereas there was no statistically significant mortality reduction with prasugrel (HR, 0.90 [95% CI, 0.80-1.01] and HR, 0.92 [95% CI, 0.84-1.02], respectively). In comparison with each other, there were no significant differences in mortality (HR prasugrel versus ticagrelor, 1.10 [95% CI, 0.94-1.29] and 1.12 [95% CI, 0.98-1.28]). In comparison with clopidogrel, prasugrel reduced myocardial infarction (HR, 0.81 [95% CI, 0.67-0.98]), whereas ticagrelor showed no risk reduction (HR, 0.97 [95% CI, 0.78-1.22]). Differences between prasugrel and ticagrelor were not statistically significant. Stent thrombosis risk was significantly reduced by both ticagrelor and prasugrel versus clopidogrel (28%-50% range of reduction). In comparison with clopidogrel, both prasugrel (HR, 1.26 [95% CI, 1.01-1.56]) and ticagrelor (HR, 1.27 [95% CI, 1.04-1.55]) significantly increased major bleeding. There were no significant differences between prasugrel and ticagrelor for all outcomes explored. CONCLUSIONS: Prasugrel and ticagrelor reduced ischemic events and increased bleeding in comparison with clopidogrel. A significant mortality reduction was observed with ticagrelor only. There was no efficacy and safety difference between prasugrel and ticagrelor. Registration: URL: https://www.crd.york.ac.uk/PROSPERO/; Unique identifier: CRD42019155648.
BACKGROUND: New randomized, controlled trials have become available on oral P2Y12 inhibitors in acute coronary syndrome. We aimed to evaluate current evidence comparing the efficacy and safety profile of prasugrel, ticagrelor, and clopidogrel in acute coronary syndrome by a meta-analysis of randomized controlled trials. METHODS: We performed a network meta-analysis and direct pairwise comparison analysis of efficacy and safety outcomes from 12 randomized controlled trials including a total of 52 816 patients with acute coronary syndrome. RESULTS: In comparison with clopidogrel, ticagrelor significantly reduced cardiovascular mortality (hazard ratio [HR], 0.82 [95% CI, 0.72-0.92]) and all-cause mortality (HR, 0.83 [95% CI, 0.75-0.92]), whereas there was no statistically significant mortality reduction with prasugrel (HR, 0.90 [95% CI, 0.80-1.01] and HR, 0.92 [95% CI, 0.84-1.02], respectively). In comparison with each other, there were no significant differences in mortality (HR prasugrel versus ticagrelor, 1.10 [95% CI, 0.94-1.29] and 1.12 [95% CI, 0.98-1.28]). In comparison with clopidogrel, prasugrel reduced myocardial infarction (HR, 0.81 [95% CI, 0.67-0.98]), whereas ticagrelor showed no risk reduction (HR, 0.97 [95% CI, 0.78-1.22]). Differences between prasugrel and ticagrelor were not statistically significant. Stent thrombosis risk was significantly reduced by both ticagrelor and prasugrel versus clopidogrel (28%-50% range of reduction). In comparison with clopidogrel, both prasugrel (HR, 1.26 [95% CI, 1.01-1.56]) and ticagrelor (HR, 1.27 [95% CI, 1.04-1.55]) significantly increased major bleeding. There were no significant differences between prasugrel and ticagrelor for all outcomes explored. CONCLUSIONS: Prasugrel and ticagrelor reduced ischemic events and increased bleeding in comparison with clopidogrel. A significant mortality reduction was observed with ticagrelor only. There was no efficacy and safety difference between prasugrel and ticagrelor. Registration: URL: https://www.crd.york.ac.uk/PROSPERO/; Unique identifier: CRD42019155648.
Authors: Stephen D Wiviott; Eugene Braunwald; Carolyn H McCabe; Gilles Montalescot; Witold Ruzyllo; Shmuel Gottlieb; Franz-Joseph Neumann; Diego Ardissino; Stefano De Servi; Sabina A Murphy; Jeffrey Riesmeyer; Govinda Weerakkody; C Michael Gibson; Elliott M Antman Journal: N Engl J Med Date: 2007-11-04 Impact factor: 91.245
Authors: Lars Wallentin; Richard C Becker; Andrzej Budaj; Christopher P Cannon; Håkan Emanuelsson; Claes Held; Jay Horrow; Steen Husted; Stefan James; Hugo Katus; Kenneth W Mahaffey; Benjamin M Scirica; Allan Skene; Philippe Gabriel Steg; Robert F Storey; Robert A Harrington; Anneli Freij; Mona Thorsén Journal: N Engl J Med Date: 2009-08-30 Impact factor: 91.245
Authors: Matthew T Roe; Paul W Armstrong; Keith A A Fox; Harvey D White; Dorairaj Prabhakaran; Shaun G Goodman; Jan H Cornel; Deepak L Bhatt; Peter Clemmensen; Felipe Martinez; Diego Ardissino; Jose C Nicolau; William E Boden; Paul A Gurbel; Witold Ruzyllo; Anthony J Dalby; Darren K McGuire; Jose L Leiva-Pons; Alexander Parkhomenko; Shmuel Gottlieb; Gracita O Topacio; Christian Hamm; Gregory Pavlides; Assen R Goudev; Ali Oto; Chuen-Den Tseng; Bela Merkely; Vladimir Gasparovic; Ramon Corbalan; Mircea Cinteză; R Craig McLendon; Kenneth J Winters; Eileen B Brown; Yuliya Lokhnygina; Philip E Aylward; Kurt Huber; Judith S Hochman; E Magnus Ohman Journal: N Engl J Med Date: 2012-08-25 Impact factor: 91.245
Authors: Stefan James; Axel Akerblom; Christopher P Cannon; Håkan Emanuelsson; Steen Husted; Hugo Katus; Allan Skene; Philippe Gabriel Steg; Robert F Storey; Robert Harrington; Richard Becker; Lars Wallentin Journal: Am Heart J Date: 2009-04 Impact factor: 4.749
Authors: Brian Hutton; Georgia Salanti; Deborah M Caldwell; Anna Chaimani; Christopher H Schmid; Chris Cameron; John P A Ioannidis; Sharon Straus; Kristian Thorlund; Jeroen P Jansen; Cynthia Mulrow; Ferrán Catalá-López; Peter C Gøtzsche; Kay Dickersin; Isabelle Boutron; Douglas G Altman; David Moher Journal: Ann Intern Med Date: 2015-06-02 Impact factor: 25.391
Authors: Marco Roffi; Carlo Patrono; Jean-Philippe Collet; Christian Mueller; Marco Valgimigli; Felicita Andreotti; Jeroen J Bax; Michael A Borger; Carlos Brotons; Derek P Chew; Baris Gencer; Gerd Hasenfuss; Keld Kjeldsen; Patrizio Lancellotti; Ulf Landmesser; Julinda Mehilli; Debabrata Mukherjee; Robert F Storey; Stephan Windecker Journal: Eur Heart J Date: 2015-08-29 Impact factor: 29.983
Authors: Jacek Kubica; Piotr Adamski; Piotr Niezgoda; Dimitrios Alexopoulos; Jolita Badarienė; Andrzej Budaj; Katarzyna Buszko; Dariusz Dudek; Tomasz Fabiszak; Mariusz Gąsior; Robert Gil; Diana A Gorog; Stefan Grajek; Paul A Gurbel; Marcin Gruchała; Miłosz J Jaguszewski; Stefan James; Young-Hoon Jeong; Bernd Jilma; Jarosław D Kasprzak; Andrzej Kleinrok; Aldona Kubica; Wiktor Kuliczkowski; Jacek Legutko; Maciej Lesiak; Jolanta M Siller-Matula; Klaudiusz Nadolny; Krzysztof Pstrągowski; Salvatore Di Somma; Giuseppe Specchia; Janina Stępińska; Udaya S Tantry; Agnieszka Tycińska; Monica Verdoia; Wojciech Wojakowski; Eliano P Navarese Journal: Cardiol J Date: 2020-10-19 Impact factor: 2.737
Authors: Jacek Kubica; Piotr Adamski; Jerzy R Ładny; Jarosław Kaźmierczak; Tomasz Fabiszak; Krzysztof J Filipiak; Robert Gajda; Mariusz Gąsior; Zbigniew Gąsior; Robert Gil; Jarosław Gorący; Stefan Grajek; Leszek Gromadziński; Marcin Gruchała; Grzegorz Grześk; Piotr Hoffman; Miłosz J Jaguszewski; Marianna Janion; Piotr Jankowski; Zbigniew Kalarus; Jarosław D Kasprzak; Andrzej Kleinrok; Wacław Kochman; Aldona Kubica; Wiktor Kuliczkowski; Jacek Legutko; Maciej Lesiak; Klaudiusz Nadolny; Eliano P Navarese; Piotr Niezgoda; Małgorzata Ostrowska; Przemysław Paciorek; Jolanta Siller-Matula; Łukasz Szarpak; Dariusz Timler; Adam Witkowski; Wojciech Wojakowski; Andrzej Wysokiński; Marzenna Zielińska Journal: Cardiol J Date: 2022-05-06 Impact factor: 3.487
Authors: Jacek Kubica; Piotr Adamski; Piotr Niezgoda; Aldona Kubica; Przemysław Podhajski; Malwina Barańska; Julia M Umińska; Łukasz Pietrzykowski; Małgorzata Ostrowska; Jolanta M Siller-Matula; Jolita Badarienė; Stanisław Bartuś; Andrzej Budaj; Sławomir Dobrzycki; Łukasz Fidor; Mariusz Gąsior; Jacek Gessek; Marek Gierlotka; Robert Gil; Jarosław Gorący; Paweł Grzelakowski; Tomasz Hajdukiewicz; Miłosz Jaguszewski; Marianna Janion; Jarosław Kasprzak; Adam Kern; Artur Klecha; Andrzej Kleinrok; Wacław Kochman; Bartosz Krakowiak; Jacek Legutko; Maciej Lesiak; Marcin Nosal; Grzegorz Piotrowski; Andrzej Przybylski; Tomasz Roleder; Grzegorz Skonieczny; Grzegorz Sobieszek; Agnieszka Tycińska; Dariusz Wojciechowski; Wojciech Wojakowski; Jarosław Wójcik; Marzenna Zielińska; Aleksander Żurakowski; Giuseppe Specchia; Diana A Gorog; Eliano P Navarese Journal: Cardiol J Date: 2021-06-07 Impact factor: 2.737
Authors: Dimitrios Venetsanos; Erik Träff; David Erlinge; Emil Hagström; Johan Nilsson; Liyew Desta; Bertil Lindahl; Linda Mellbin; Elmir Omerovic; Karolina Elisabeth Szummer; Sammy Zwackman; Tomas Jernberg; Joakim Alfredsson Journal: Heart Date: 2021-03-12 Impact factor: 5.994
Authors: Ioannis T Farmakis; Stefanos Zafeiropoulos; Ioannis Doundoulakis; Areti Pagiantza; Efstratios Karagiannidis; Dimitrios V Moysidis; Nikolaos Stalikas; George Kassimis; Lampros K Michalis; Haralambos Karvounis; George Giannakoulas Journal: Open Heart Date: 2022-04